J&J outlays up to $3.3bn to buy ophthalmology specialist Ollin Biosciences
Johnson & Johnson (J&J) is betting on differentiated treatments for eye conditions such as wet age-related macular degeneration (AMD), spending…
Johnson & Johnson (J&J) is betting on differentiated treatments for eye conditions such as wet age-related macular degeneration (AMD), spending…
Revolution Medicines’ pancreatic cancer drug Rasonque (daraxonrasib) may have breezed through a regulatory approval in the US, but rolling out the treatment across patient groups remains complex. Speaking at the…
Massachusetts-based biotech venture firm Flagship Pioneering has initially committed £100m ($131m) to its UK presence by building a new company creation unit, marking another positive step forward for the country…
European venture capital (VC) giant, Sofinnova Partners, has closed a €725m ($815m) fund to support a range of life sciences companies through clinical development, commercialisation and global expansion. The Crossover…
The US Food and Drug Administration (FDA) has approved AstraZeneca's Imfinzi (durvalumab) in combination with Padcev (enfortumab vedotin) for adult patients with muscle-invasive bladder cancer (MIBC) who cannot receive or have…
The US Food and Drug Administration (FDA) has declined to approve Summit Therapeutics’ biologics licence application (BLA) for ivonescimab in patients with locally advanced or metastatic non-small cell lung cancer…
Following the US midterm elections, Arizona Senator Mark Kelly used day one of HLTH 2026 in Las Vegas to set out the Democrats' emerging healthcare priorities, against a backdrop of…